Antitumor activity of the oncolytic peptide LTX-315 in syngeneic tumor models

被引：0
|
作者：
Camilio, Ketil Andre
Sveinbjornsson, Baldur
Maubant, Sylvie
Serin, Guillaume
Mirjolet, Jean-Francois
Bichat, Francis
Rekdal, Oystein
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-328
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
328
引用
收藏
页数：4
相关论文
共 50 条
  • [21] IMMUNOTHERAPEUTIC AND ANTIMETASTATIC ACTIVITY OF LTX-315 IN PRECLINICAL MODELS OF ICI-RESISTANT BREAST CANCER
    Yamazaki, Takahiro
    Wennerberg, Erik
    Hensler, Michal
    Martinez, Aitziber Buque
    Kraynak, Jeffrey
    Fucikova, Jitka
    Zhou, Xi
    Sveinbjornsson, Baldur
    Rekdal, Oystein
    Demaria, Sandra
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A589 - A589
  • [22] LTX-315 (Oncopore™) A short synthetic anticancer peptide and novel immunotherapeutic agent
    Camilio, Ketil Andre
    Rekdal, Oystein
    Sveinbjornsson, Baldur
    ONCOIMMUNOLOGY, 2014, 3 (06)
  • [23] Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report
    Nina Louise Jebsen
    Torunn Oveland Apelseth
    Hans Kristian Haugland
    Øystein Rekdal
    Hamina Patel
    Bjørn Tore Gjertsen
    Dag Eirik Jøssang
    Journal of Medical Case Reports, 13
  • [24] Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report
    Jebsen, Nina Louise
    Apelseth, Torunn Oveland
    Haugland, Hans Kristian
    Rekdal, Oystein
    Patel, Hamina
    Gjertsen, Bjorn Tore
    Jossang, Dag Eirik
    JOURNAL OF MEDICAL CASE REPORTS, 2019, 13 (01)
  • [25] The oncolytic peptide LTX-315 enhances tumor-specific immune responses and tumor regression in murine 4T1 breast cancer when combined with doxorubicin
    Wang, Meng Yu
    Kristian, Alexander
    Camilio, Ketil
    Sveinbjornsson, Baldur
    Maelandsmo, Gunhild Mari
    Kvalheim, Gunnar
    Rekdal, Oystein
    CANCER RESEARCH, 2016, 76
  • [26] Efficient Delivery of Oncolytic Peptide LTX-315 by ZIF-8: pH-Responsive Release, Improved Stability, and Reduced Hemolysis
    Chen, Xin-Qi
    Cui, Su-Su
    Chen, Yu-Zhen
    Wang, Cai-Yun
    Liu, Qing
    Qi, Yun-Kun
    Du, Shan-Shan
    MOLECULAR PHARMACEUTICS, 2025, 22 (03) : 1449 - 1461
  • [27] Oncolytic peptide LTX-315 enhances anti-melanoma immunity by inducing MyD88-dependent maturation of dendritic cells
    De Yang
    Li, Xiao-Qing
    Alam, Md Masud
    Rekdal, Oystein
    Oppenheim, Joost J.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [28] A phase I study of the oncolytic peptide LTX-315 generatesde novoT-cell responses and clinical benefit in patients with advanced sarcoma
    Baaurain, Jean-Francois
    Jungels, Christiane
    Kristeleit, Rebecca S.
    Jossang, Dag E.
    Jebsen, Nina L.
    Rekdal, Oystein
    Sveinbjornsson, Baldur
    Gjerstad, Vibeke S.
    Brunsvig, Paal
    Galon, Jerome
    Hermitte, Fabienne
    Patel, Hamina
    CANCER RESEARCH, 2019, 79 (13)
  • [29] In vitro activities of the cationic antitumoral peptide LTX-315 against human melanoma cells
    Eike, Liv-Marie
    Yang, Nannan
    Rekdal, Oystein
    Sveinbjornsson, Baldur
    CANCER RESEARCH, 2014, 74 (19)
  • [30] LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects
    Liao, Hsin-Wei
    Garris, Christopher
    Pfirschke, Christina
    Rickelt, Steffen
    Arlauckas, Sean
    Siwicki, Marie
    Kohler, Rainer H.
    Weissleder, Ralph
    Sundvold-Gjerstad, Vibeke
    Sveinbjornsson, Baldur
    Rekdal, Oystein
    Pittet, Mikael J.
    CELL STRESS, 2019, 3 (11) : 348 - 360
12345